Previous 10 | Next 10 |
MARINA DEL REY, Calif. , Oct. 10, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has expanded i...
MARINA DEL REY, Calif. , Sept. 19, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that management will be particip...
MARINA DEL REY, Calif. , Sept. 12, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the "Company" or "Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced...
Armata Pharmaceuticals (NYSEMKT: ARMP ): Q2 GAAP EPS of -$0.69 misses by $0.25 . More news on: Armata Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
MARINA DEL REY, Calif. , Aug. 14, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced secon...
The following slide deck was published by Armata Pharmaceuticals, Inc. in conjunction with this Read more ...
MARINA DEL REY, Calif. , Aug. 1, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that Brian Varnum , PhD, Pre...
Gainers: Melinta Therapeutics (NASDAQ: MLNT ) +180% . Arcturus Therapeutics (NASDAQ: ARCT ) +37% . Hebron Technology (NASDAQ: HEBT ) +26% . MYOS RENS Technology (NASDAQ: MYOS ) +22% . Armata Pharmaceuticals (NYSEMKT: ARMP ) +19% . AquaBounty Technologies (NASDAQ: AQB ) +19% . D...
MARINA DEL REY, Calif. , June 18, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will host a Key Opinion L...
Armata Pharmaceuticals (NYSEMKT: ARMP ) is granted two patents by the European Patent Office and one by the Canadian Intellectual Property Office covering various aspects of it's bacteriophage program, and AP-SA01, which is in development against various diseases or indications caused by S...
News, Short Squeeze, Breakout and More Instantly...
Armata Pharmaceuticals Inc. Company Name:
ARMP Stock Symbol:
NYSE Market:
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology com...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 20...
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit PR Newswire LOS ANGELES , Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on...